Journal ArticleOPEN ACCESS

Rybelsus: an oral formulation of the GLP ‐1 agonist semaglutide

  • Chaplin S
Prescriber (2020) 31(10) 32-33
DOI: 10.1002/psb.1873
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Rybelsus (semaglutide) is the first GLP‐1 agonist for the treatment of type 2 diabetes to be available as an oral formulation. This article discusses its properties, efficacy and adverse effects.

Cite

CITATION STYLE

APA

Chaplin, S. (2020). Rybelsus: an oral formulation of the GLP ‐1 agonist semaglutide. Prescriber, 31(10), 32–33. https://doi.org/10.1002/psb.1873

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free